Peptides explained
Tesamorelin: how it works
Page updated · Sources and editorial approach
Tesamorelin acts on growth-hormone-releasing hormone pathways. Learn about visceral-fat trials, its specific US indication and important evidence limits.
Tesamorelin at a glance
What it does biologically
It stimulates the body's growth-hormone pathway through a GHRH receptor mechanism, increasing downstream IGF-1.
What the evidence shows
Human trials concern defined populations, particularly excess abdominal fat in adults with HIV-associated lipodystrophy.
What remains uncertain
Those findings do not establish general weight-loss, anti-ageing or performance benefits.
The basics
What is Tesamorelin?
Tesamorelin is an analogue of growth hormone-releasing hormone, also called growth hormone-releasing factor. It acts upstream of growth hormone and IGF-1 rather than supplying IGF-1 LR3 itself.
The US medicine EGRIFTA has a specific indication involving excess abdominal fat in adults with HIV-associated lipodystrophy. The official label explicitly states that it is not indicated for weight-loss management. That indication cannot be broadened to all people seeking to lose fat.
Biological action
How does Tesamorelin work?
Stimulation of the pituitary growth-hormone pathway can increase circulating growth hormone and IGF-1. This differs from incretin medicines, which act on GLP-1 or GIP pathways, and from administering a growth-factor analogue directly.
Visceral adipose tissue surrounds internal organs; subcutaneous fat sits beneath the skin. A change in one compartment is not automatically a comparable change in total body weight or in the other compartment.
Questions being investigated
What do studies examine?
Visceral fat
Randomised trials measured CT-defined abdominal visceral fat in selected patients with HIV-associated fat accumulation.
Liver fat
A smaller trial studied liver fat alongside visceral fat, with further research needed to establish longer-term importance.
Endocrine safety
The official label addresses increased IGF-1, fluid retention, glucose intolerance and malignancy-related precautions.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | GHRH-receptor pharmacology explains stimulation of the growth-hormone axis. |
| Animal | Preclinical findings do not substitute for the specific human trials. |
| Human | Randomised trials exist in defined HIV-associated lipodystrophy populations. |
| Regulatory | US EGRIFTA authorisation is product- and indication-specific; it is not general weight-loss approval. |
Important context
Risks, limitations and unanswered questions
- Visceral-fat outcomes are not general weight-loss outcomes.
- Long-term cardiovascular safety is not established in the official label.
- Growth-hormone and IGF-1 changes bring monitoring and safety concerns.
- Evidence must match the exact authorised formulation and population.
Reading the original evidence
The clinical context matters
The cited trial studied a growth-hormone-releasing factor in people with HIV and assessed metabolic outcomes. That population is part of the evidence, not an optional detail. A result from that setting does not establish general weight-loss or physique effects in healthy people.
Question to take to the source: Does the summary preserve the diagnosed condition and the exact fat or metabolic endpoint studied?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Questions answered
Tesamorelin FAQs
Is tesamorelin a GLP-1 drug?
No. It is a GHRH analogue acting through the growth-hormone axis.
Is it approved for general weight loss?
The US EGRIFTA label explicitly says it is not indicated for weight-loss management.
Is tesamorelin the same as IGF-1 LR3?
No. Tesamorelin stimulates hormone release upstream; LR3 is a modified IGF-1 analogue.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Falutz et al.: visceral-fat randomised trial ↗Primary 26-week trial in 412 people with HIV-associated abdominal fat accumulation.
- Stanley et al.: visceral and liver fat trial ↗Primary randomised trial; results apply to the studied HIV population.
- EGRIFTA WR official US label ↗Product-specific indication, limitations and safety information.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.